Log in to search using one of your social media accounts:

 

Primary Central Nervous System Post-transplant Lymphoproliferative Disorder Diagnosed by Peripheral Facial Nerve Palsy.

Primary Central Nervous System Post-transplant Lymphoproliferative Disorder Diagnosed by Peripheral Facial Nerve Palsy. Intern Med. 2018 Feb 09;: Authors: Imafuku A, Tanaka K, Marui Y, Ubara Y, Takaichi K, Tomikawa S, Ota Y, Fujii T, Ishii Y Abstract Although primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD) causes various symptoms depending on the tumor region, there has been no previous report of PCNS-PTLD in the cerebellopontine angle that was diagnosed due to peripheral facial nerve palsy. We herein report a case involving a 62-year-old man with PCNS-PTLD in the cerebellopontine angle who was diagnosed due to peripheral facial nerve palsy. The reduction of immunosuppressive therapy, whole-brain radiotherapy, intrathecal chemotherapy, and rituximab were effective in treating this patient. Physicians should therefore be mindful that PCNS-PTLD can cause peripheral facial nerve palsy in renal transplant recipients. PMID: 29434151 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research

Related Links:

Last year, the Food and Drug Administration approved two new immunotherapies to treat certain leukemias and lymphomas. Now, in a study published in the New England Journal of Medicine, researchers detail who is most likely to benefit from the treatments, called CAR T cell therapy. CAR T cell therapy trains the body’s immune system to target and destroy cancer cells in the blood; scientists take people’s own immune cells (T cells) and genetically engineer them to seek out and destroy cancer cells. The immune system can then attack cancer cells in the same way it does bacteria and viruses, and the therapy can lea...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer cancer cells cancer immunotherapy CAR T car t cell therapy car t gene therapy car t therapy cure for cancer healthytime leukemia leukemia treatments Source Type: news
Background: Primary central nervous system lymphoma (PCNSL) is a rare subtype of non-Hodgkin lymphoma and carries a poor prognosis. Given the high rates of neurotoxicity associated with whole brain radiotherapy, there has been considerable interest in using high dose chemotherapy consolidation with autologous stem cell rescue (HDC-ASCT) to manage these patients.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
In conclusion, death is a natural part of human existence, but human progress is essentially a story of overcoming undesirable natural limits. In the near future, technological progress might make it possible to stop natural biological death. Should humankind embrace such technology? Yes: Even though such technology would not be without risks, the risks are almost certainly manageable. The benefits of ending natural death, on the other hand, are immense. Death is an obstacle that is slowing down human progress. If we remove that obstacle, humankind could increase the speed of both its moral and its epistemic progress. ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Discussion of advocacy for the cause is a usual feature of our community, as we try things and attempt to make progress in persuading the world that rejuvenation research is plausible, practical, and necessary. There are more people engaged in advocacy now than at any time in the past decade, and so discussions of strategy come up often. New ventures kicked off in 2017 include the Geroscience online magazine, and among the existing ventures the LEAF / Lifespan.io volunteers seem to be hitting their stride. The mainstream media continues to be as much a hindrance as a help, and where it is a help you will usually find Aubre...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
When a neurosurgeon looks at a glioblastoma, an aggressive form of brain cancer, she sees a dark mass bullying its way through the brain. When an oncologist talks to a patient with glioblastoma, he tempers expectations, talking in months rather than years. When a molecular biologist thinks about glioblastoma, she thinks about the tumor ’s sweet tooth — the sugar it consumes to fuel its frenetic growth. And when you put all these people together — you get a plan to fight cancer.Armed with new research tools and a grant from the David Geffen School of Medicine ’s newSeed Grant Program, a team of UCLA ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Ladies and Gentlemen, this is the moment you have all been waiting for – the day that the winners of the Medgadget Medical Sci-Fi Competition are announced and their fantastic stories are published! First, we would like to thank Eko Devices, th...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Source Type: blogs
Authors: Ferreri AJM Abstract Primary central nervous system (CNS) lymphomas represent a subgroup of malignancies with specific characteristics, an aggressive course, and unsatisfactory outcome in contrast with other lymphomas comparable for tumor burden and histological type. Despite the high sensitivity to conventional chemotherapy and radiotherapy, remissions are frequently short lasting. Treatment efficacy is limited by several factors, including the biology and microenvironment of this malignancy and the "protective" effect of the blood-brain barrier, which limits the access of most drugs to the CNS....
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
This article provides an overview of the clinical features, diagnosis, and management of primary CNS lymphoma in patients who are immunocompetent, focusing on recent advances in treatment. Recent Findings: Primary CNS lymphoma is sensitive to radiation therapy; however, whole-brain radiation therapy inadequately controls the disease when used alone and causes delayed neurotoxicity with significant neurocognitive impairment, especially in patients who are elderly. A number of clinical trials have demonstrated durable disease control and less neurotoxicity with methotrexate-based induction chemotherapy with or without autol...
Source: CONTINUUM: Lifelong Learning in Neurology - Category: Neurology Tags: Review Articles Source Type: research
This study is registered with ClinicalTrials.gov, number NCT01011920. Findings Between Feb 19, 2010, and Aug 27, 2014, 227 patients were recruited from 53 centres in five countries. 219 of 227 enrolled patients were assessable. Of the 122 patients eligible for the second randomisation, 118 patients were randomly assigned to WBRT or ASCT (59 patients per group) and constitute the study population. WBRT and ASCT were both effective, and achieved the predetermined efficacy threshold of at least 40 progression-free survivors at 2 years among the first 52 patients in both groups D and E. There were no significant differences in...
Source: The Lancet Haematology - Category: Hematology Source Type: research
More News: Brain | Brain Cancers | Chemotherapy | Internal Medicine | Neurology | Rituxan | Transplants